People · Operator
Named in public records as an officer, director or promoter · active 2013–2025 · Pharmaceuticals, Other Technology, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ardelyx, Inc. | — | Pharmaceuticals | Series D+ | $210.4M | $3.9B | 2016 |
| Nemus Bioscience, Inc. | — | Pharmaceuticals | Series C | $168.4M | $388.7M | 2024 |
| Dimension Therapeutics, Inc. | — | Other Technology | Series C | $94.5M | $2.0B | 2013 |
| Prosensa Holding N.V. | — | Biotechnology | Series C | $50.5M | $2.1B | 2014 |
| Vium, Inc. | — | Other | Series B | $35.4M | $38.8M | 2017 |
| ONCOSEC MEDICAL Inc | — | Biotechnology | Series A | $13.6M | $205.5M | 2017 |
| Cocoon Biotech Inc. | — | Biotechnology | Series A | $7.8M | $8.2M | 2017 |
| EtiraRX, Inc. | — | Biotechnology | Series A | $7.2M | $8.0M | 2025 |
Annalisa Jenkins at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Annalisa Jenkins on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Mott | 2 | 9 |
| Punit Dhillon | 2 | 4 |
| Andrew Schwab | 1 | 16 |
| Matt Ocko | 1 | 13 |
| Rishi Gupta | 1 | 12 |
| David Collier | 1 | 8 |
| Thomas Beck | 1 | 7 |
| Gordon Ringold | 1 | 7 |
| PAUL Grayson | 1 | 5 |
| Praveen Tyle | 1 | 5 |
| Donald J. Hayden, Jr. | 1 | 5 |
| Jay K. Hachigian | 1 | 5 |
| Daniel O'Connor | 1 | 5 |
| Michael Wyzga | 1 | 5 |
| Armen Vidian | 1 | 5 |
| Anthony Maida | 1 | 5 |
| Richard Rodgers | 1 | 4 |
| Jeremy Caldwell | 1 | 4 |
| Luc Dochez | 1 | 4 |
| Avtar Dhillon | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.